EUCTR2011-004432-58-Outside-EU/EEA进行中（未招募）不适用
Phase III, open-label, and mono-center booster vaccination study in toddlers who completed a three-dose primary series of DTaP-IPV-Hep B-PRP-T combined vaccine or of Pentaxim™ and Engerix™ B in Study A3L10.
Sanofi Pasteur SA0 个研究点目标入组 254 人开始时间: 2012年4月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 254
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Toddler previously included in Study A3L10 who completed the three dose primary series vaccination of either DTaP-IPV-Hep B-PRP-T or Pentaxim™ and Engerix™ B at 2, 3, and 4 months of age
- •2) Toddler of 15 to 18 months of age (range: 456 to 578 days of age inclusive)
- •3) Informed Consent Form signed by the parent(s) or other legal representative(s) and an institution official other than an Investigator
- •4) Able to attend all scheduled visits and to comply with all trial procedures
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 254
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Participation in another clinical trial in the 4 weeks preceding the booster vaccination
- •2) Planned participation in another clinical trial during the present trial period
- •3) Congenital or acquired immunodeficiency, and immunosuppressive therapy such as long term systemic corticosteroid therapy
- •4) Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to a vaccine containing the same substances
- •5) Chronic illness at a stage that could interfere with trial conduct or completion
- •6) Blood or blood derived products received in the last 3 months
- •7) Any vaccination in the 4 weeks preceding the booster vaccination
- •8) Any vaccination planned until Visit 02
- •9) History of documented pertussis, tetanus, diphtheria, polio, Haemophilus influenzae type b or hepatitis B infection(s) (confirmed either clinically, serologically or microbiologically)
- •10) Previous booster vaccination against pertussis, tetanus, diphtheria, polio or Haemophilus influenzae type b, and hepatitis B infection(s)
- •11) Coagulopathy, thrombocytopenia, or a bleeding disorder contraindicating intramuscular vaccination
- •12) Any vaccine related SAE that occurred following the three dose primary series administration of the investigational vaccine or of the reference vaccine in Study A3L10
- •13) Febrile (temperature > or =38.0°C) or acute illness on the day of inclusion
- •14) Known contraindication to further vaccination with a pertussis vaccine, i.e.
- •- Encephalopathy
- •- Temperature >40.0°C within 48 hours following a vaccine injection, not due to another identifiable cause during the primary series
- •- Inconsolable crying that occurred for >3 hours within 48 hours following vaccine injection during the primary series
- •- Hypotonic hyporesponsive episode within 48 hours following vaccine injection during the primary series
- •- Seizures with or without fever within 3 days following vaccine injection
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity Study of the Antibody Persistence and Booster Effect of the DTaP-IPV-Hep B-PRP-T Combined Vaccine at 15 to 18 Months of Age Following a Primary Series of DTaP-IPV-Hep B-PRP-T or Infanrix hexa™ Administered at 2, 4, and 6 Months of Age in Healthy Mexican InfantsPrevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus influenzae type b and infection caused by hepatitis B virusMedDRA version: 14.1Level: PTClassification code 10021430Term: ImmunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: LLTClassification code 10036897Term: Prophylactic vaccinationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: HLTClassification code 10021431Term: ImmunisationsSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: HLGTClassification code 10043413Term: Therapeutic procedures and supportive care NECSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2011-004456-19-Outside-EU/EEASanofi Pasteur S.A1,190
进行中（未招募）
1 期
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Patients with Hemophilia BHemophilia BEUCTR2012-005489-37-ESCSL Behring GmbH97
进行中（未招募）
1 期
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Patients with Hemophilia BHemophilia BEUCTR2012-005489-37-ATCSL Behring GmbH99
进行中（未招募）
1 期
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Patients with Hemophilia BHemophilia BEUCTR2012-005489-37-CZCSL Behring GmbH115
进行中（未招募）
1 期
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Patients with Hemophilia BHemophilia BEUCTR2012-005489-37-DECSL Behring GmbH96